Navigation Links
Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
Date:2/19/2013

on, as a result of the inclusion of legacy Actavis results.

For the full year 2012, Actavis Pharma net revenue increased 32 percent to $4.45 billion, including product sales of $4.39 billion and other revenue of $61.0 million, primarily due to higher international revenues as a result of the acquisitions of Ascent and the Actavis Group in January 2012 and November 2012, respectively, as well as full year sales of the authorized generic versions of Concerta® and Lipitor® in the U.S., launched in May 2011 and November 2011, respectively. 

Actavis Pharma's adjusted gross margin increased from 46.2 percent in 2011 to 46.6 percent in 2012.Actavis Specialty Brands Segment InformationThree Months EndedTwelve Months EndedDecember 31,December 31, (Unaudited; $ in millions)2012201120122011Product sales

$
2.6$
.1$
411.6$
364.9Other revenue

19.620.870.876.1Net revenue

132.2120.9482.4441.0Operating expenses:Cost of sales

30.626.1115.494.4Research and development

30.76.9146.267.7Selling and marketing

45.346.5175.5168.6Segment contribution

$
25.6$
41.4$
45.3$
.3Segment margin

19.4%34.2%9.4%25.0%Adjusted gross profit (1)

$
.6$
94.8$
367.0$
347.2Adjusted gross margin

76.9%78.4%76.1%78.7%(1)Adjusted gross profit represents net revenue less

adjusted cost of sales and excludes amortization of

acquired intangibles. Pro forma adjustments for the

respective periods include the following: Acquisition and licensing

$
-$
-$
-$
.6Actavis Specialty Brands net revenue increased 9 percent to $132.2 million in the fourth quarter. The increase was due to higher sales of key promoted products including Generess® Fe and Rapaflo® and the addition of Kadian®, which was acquired with the acquisition
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Aethlon Medical Note: Fiscal Year Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... -- Huntington Memorial Hospital is the first facility in ... replacement (TAVR), a minimally invasive replacement of heart valves. ... replace an aortic valve without a chest incision or ... The procedure is performed by a dedicated Huntington Hospital ... , MD, interventional cardiologist and Robbin Cohen , ...
(Date:3/26/2015)... March 26, 2015  OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... clinical developments and announced fourth quarter and year ... Developments and Anticipated Near-term MilestonesCustirsen , ... to negotiate the termination of their collaboration and ... final termination agreement are ongoing. , Two ...
(Date:3/26/2015)... According to a new market research report ... Cryoablation, Others), Department (Interventional Radiology, Surgery, Oncology), Application (Liver ... Forecasts to 2019", published by MarketsandMarkets, the Tumor Ablation ... at a CAGR of 11.50% by 2019. ... through 195 pages and in-depth TOC on "Tumor Ablation ...
Breaking Medicine Technology:Huntington Memorial Hospital Performs Groundbreaking Minimally Invasive Replacement of Heart Valves 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8Tumor Ablation Market Worth $462.0 Million by 2019 2Tumor Ablation Market Worth $462.0 Million by 2019 3Tumor Ablation Market Worth $462.0 Million by 2019 4
... that it will report its 2010 year-end earnings on Thursday, April ... an analyst and investor call at 9:00 AM EDT live via ... in the conference call within the U.S. and Canada, dial (866) ... (708) 290-1340. The conference ID is 58484489. ...
... Boston Scientific Corporation (NYSE: BSX ... (FDA) approval and launch of the ION™ Paclitaxel-Eluting ... drug-eluting stent technology.  The ION Stent System incorporates ... for coronary stenting and intended to improve the ...
Cached Medicine Technology:Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 2Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 3Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 4Boston Scientific Announces FDA Approval and U.S. Launch of ION™ Platinum Chromium Stent System 5
(Date:3/28/2015)... LTW Cyber is an innovation hub for technology ... of addressing the needs of the global market for ... to grow while seeking collaborative opportunities with the other ... in LTW Cyber focus on secure application security, grounded ... and analyzing open source. As the hub matures, ...
(Date:3/27/2015)... March 27, 2015 The federal court ... allege the statin medication increases the risk that a ... Inc.’s Motion to Dismiss four individual cases that had ... Management Order issued in the U.S. District Court, District ... that the dismissals were warranted because the plaintiffs in ...
(Date:3/27/2015)... California (PRWEB) March 27, 2015 ... Entertainment’s EcoLuxe Lounge in the Stardust Penthouse on ... Debbie Durkin, Los Angeles’ leading sustainable product TV ... behind this unforgettable day-long event, which featured some ... and ecologically sound products and services. , “We ...
(Date:3/27/2015)... According to a recently published report series ... screw market in Europe is in decline due to ... segment. Price decreases are being seen across the entire ... the total European trauma device market, continued pricing pressure ... year after year. , “Such price drops are ...
(Date:3/27/2015)... According to Health Day , on March 6th, ... (NAS) are causing alarm for Florida officials. Infants born ... a month of their lives- and can experience seizures, ... condition is precipitated by drug use during pregnancy. Unfortunately, ... medically assisted drug treatment) will also inflict NAS on ...
Breaking Medicine News(10 mins):Health News:Canadian Cybersecurity Ventures Globalize as a Collective 2Health News:Canadian Cybersecurity Ventures Globalize as a Collective 3Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 2Health News:Lipitor Lawsuits Move Forward in Federal Multidistrict Litigation, as Court Rules on Pfizer’s Motion to Dismiss Certain Cases 3Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 2Health News:Titanium Trauma Treatment Devices in Europe Becoming More Affordable, Decreasing Market Value: Group Purchasing Further Eroding Selling Prices 3Health News:In Florida Only 10% of Pregnant Mothers Are Referred to Drug Rehab Despite Testing Positive for Narcotics 2
... , MONDAY, March 7 (HealthDay News) -- Sleep tight, but ... message of a new survey that suggests many Americans might ... bedtime in front of the electronic glow of a television, ... exposure to bright light before bed disrupts sleep. But some ...
... , MONDAY, March 7 (HealthDay News) -- Genetics ... -- where fear and stress are a fact of daily ... decline, new research warns. The culprit is a specific ... that while this gene is known to play a key ...
... , MONDAY, March 7 (HealthDay News) -- Young adults ... less likely to achieve the same level of education ... Improved medical care over the past 40 years has ... surviving into adulthood. However, they carry the burden of ...
... less treatment in the American health care system than their ... dose of empathy helps close racial gaps in pain treatment. ... ease the pain of members of their own race in ... at the University of Wisconsin-Madison. "I want to be ...
... identified a critical part of the process by which ... childhood infections, respiratory syncytial virus, causes disease. ... for RSV, which in 2005 was estimated to have ... among children under five worldwide. By analyzing samples ...
... tumor growth, and naturally mounts an anti-cancer defense. Dendritic ... present them to T cells, and those "primed" T ... cells. In recent years, researchers have attempted to capitalize ... namely, by generating a pool of tumor antigen-pulsed DCs ...
Cached Medicine News:Health News:Using Electronics Before Bed May Hamper Sleep 2Health News:Using Electronics Before Bed May Hamper Sleep 3Health News:Mix of Genetics and Stress Can Impair Mental Abilities 2Health News:Surviving Serious Childhood Illness Takes Toll Later: Study 2Health News:Surviving Serious Childhood Illness Takes Toll Later: Study 3Health News:New perspective diminishes racial bias in pain treatment 2Health News:Scientists find key mechanism of childhood respiratory disease 2Health News:Scientists find key mechanism of childhood respiratory disease 3
Light weight adjustable trial frame, adult...
Classic Trial Frames UB3 that has long set the standard....
Non Sterile surgical blade....
BD Beaver Cataract blade, 30.0 mm long x 2.2 mm wide, designed for ICCE and ECCE procedures, designed for ICCE and ECCE, sterile....
Medicine Products: